Fewer than a tenth of individuals that would benefit from obesity jabs like Wegovy are able to get them, caution the global health agency as it publishes its initial advice on the medications.
Considering in excess of 1,000,000,000 people worldwide now obese, it is advocating for broader and more equitable availability to these injectable treatments.
According to projections, more than two billion are projected to be living with obesity by 2030 without intervention.
"The new guidelines affirms that obesity is a long-term condition that can be addressed with thorough and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are key barriers to broad availability to the treatments that can help people shift considerable weight, says the organization.
Weight-Loss Drug Scarcity
Despite the current best projected case, the production of these medications would only suffice for around 100 million people – fewer than 10% of the global need, per the health organization.
The advice urges countries and companies to expand access, via approaches like licensing agreements.
A patent on semaglutide – the main component of the drug Wegovy – is due to expire in a number of nations in 2026.
The Way Obesity Jabs Function
These medications mimick a body's own hormone to reduce digestion speed, curb appetite and boost feelings of fullness so people reduce food intake.
Individuals usually see weight reduction in the initial weeks of commencing the weekly injections.
Evidence indicates users may regain a significant portion after a year of discontinuing the medication, when their typical appetite come back.
Being above a healthy weight elevates your risk for experiencing medical conditions, like diabetes, heart disease, brain attack, and some malignancies.
Obesity affects individuals in all nations and was associated with 3.7 million deaths worldwide in 2024, per the health agency.
